🔍

PRIVISCL - Privi Speci.

📊 NSE: PRIVISCL 🏢 Chemicals 📅 Last Updated: 12/14/2025 11:18

📢 Recent Corporate Announcements

Privi Speciality Chemicals Invests ₹1.78 Cr for 5.8% Stake in Solar SPV

🟢 POSITIVE ⭐ 4/10

EXPANSION 📅 10 Mar 2026, 06:04 PM

Privi Speciality Chemicals has completed an investment of ₹1.78 crore in Radiance MH Sunrise Eleven Private Limited to acquire a 5.80% equity stake. This strategic move allows the company to become a captive user of solar power, reducing its reliance on traditional energy sources like coal and natural gas. The investment involves the acquisition of 47,103 equity shares at a price of ₹377 per share. This initiative is expected to lead to a reduction in the company's overall electricity costs while improving its environmental sustainability profile.

Invested ₹1,77,57,831 to acquire a 5.80% stake in a solar power SPV
Acquired 47,103 equity shares at ₹377 per share (including ₹367 premium)
The SPV is developing a 16.60 MW solar electric generating facility in Maharashtra
Aims to reduce operational costs and dependence on coal and natural gas through captive consumption
Transaction completed in a single tranche on March 09, 2026

💡 This is a minor but positive operational update that highlights the company's focus on cost optimization and ESG goals. No immediate action is required, but it reflects well on management's efforts to improve long-term margins.

Privi Speciality Chemicals Cancels Analyst Meeting Scheduled for February 18, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 17 Feb 2026, 04:35 PM

Privi Speciality Chemicals Limited has officially cancelled its scheduled interaction with analysts and institutional investors. The meetings were originally part of the Dolat Capital Corporate Conference 2026, which was set to take place in Mumbai on February 18, 2026. The company had previously disclosed this schedule on February 12, 2026, but has now informed the exchanges of the cancellation without citing a specific reason. This is a procedural update and does not impact the company's financial fundamentals.

Cancellation of 1x1 and Group Meetings originally scheduled for February 18, 2026.
The interaction was organized by Dolat Capital as part of their 2026 Corporate Conference.
The company had initially notified the stock exchanges about this meeting on February 12, 2026.
The scheduled start time for the interaction was 9:00 am onwards in Mumbai.

💡 No immediate action is required as this is a routine administrative update regarding investor relations. Investors should monitor for any future announcements regarding rescheduled management interactions.

Privi Speciality Q3 FY26 PAT Surges 84% in 9M; Targets ₹5,000 Cr Revenue in 3-4 Years

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 16 Feb 2026, 05:51 PM

Privi Speciality Chemicals reported a robust Q3 FY26 with revenue growing 25% YoY to ₹611.15 crores and EBITDA margins sustaining above 25% for the third consecutive quarter. The company is aggressively pursuing its '5k:1k' vision, aiming for ₹5,000 crores in revenue and ₹1,000 crores in EBITDA within 3-4 years. Operational highlights include a capacity expansion from 48,000 MT to 54,000 MT expected by April 2026 and a strategic debt reduction in the Prigiv JV through interest-free advances from Givaudan. Management expects 11-15% volume growth next year, supported by a favorable trade landscape in the US and Europe.

9M FY26 adjusted PAT grew by 84% YoY to ₹232 crores, driven by operational efficiencies and product mix.
EBITDA margins remained strong at 25.83% for Q3, with management guiding for a 20-27% range going forward.
Phase 1 capacity expansion to 54,000 MT is on track for commercialization by March/April 2026.
Givaudan to provide non-interest-bearing trade advances to the Prigiv JV to significantly reduce debt and interest costs.
Company plans a 3-phase expansion to increase overall capacity by 55% over the next 2-3 years.

💡 Investors should maintain a positive outlook given the company's consistent margin profile and clear 2x revenue growth roadmap. The strengthening partnership with Givaudan and upcoming capacity additions provide strong earnings visibility for the next 24 months.

Privi Speciality Chemicals to Participate in Investor Conferences in February 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 12 Feb 2026, 05:00 PM

Privi Speciality Chemicals Limited has scheduled two major investor interactions in February 2026. The company will participate in the Dolat Capital Corporate Conference on February 18 and the IIFL 17th Enterprising India Global Investors' Conference on February 26. These meetings will be held in Mumbai and will include both 1x1 and group interaction formats. The company has clarified that only publicly available information will be discussed, ensuring no unpublished price sensitive information is shared.

Scheduled meeting with investors at Dolat Capital Corporate Conference on February 18, 2026
Participation in IIFL's 17th Enterprising India Global Investors' Conference on February 26, 2026
Interactions will consist of 1x1 and group meetings held in Mumbai
Company explicitly stated that no unpublished price sensitive information (UPSI) will be disclosed

💡 Investors should monitor for any investor presentations or transcripts released following these conferences for insights into management's outlook. No immediate trading action is required based on this routine scheduling update.

Privi Speciality Chemicals to Attend Investor Conferences on February 18 and 26, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 12 Feb 2026, 04:59 PM

Privi Speciality Chemicals Limited has announced its participation in two major investor conferences in February 2026. The company will first attend the Dolat Capital Corporate Conference in Mumbai on February 18, featuring 1x1 and group meetings starting at 9:00 AM. This will be followed by participation in IIFL's 17th Enterprising India Global Investors' Conference on February 26. The management has clarified that discussions will be limited to publicly available information with no disclosure of unpublished price-sensitive data.

Scheduled 1x1 and group meetings at the Dolat Capital Corporate Conference on February 18, 2026
Participation in IIFL's 17th Enterprising India Global Investors' Conference on February 26, 2026
Meetings are part of routine investor relations under SEBI Regulation 30(6)
Company explicitly stated that no Unpublished Price Sensitive Information (UPSI) will be discussed

💡 Investors should monitor the exchange for any investor presentations or transcripts that may be uploaded following these conferences. While routine, these meetings can provide insights into management's outlook on the speciality chemicals sector.

Privi Speciality Chemicals Shares Q3 FY26 Earnings Call Audio Recording

🟡 NEUTRAL ⭐ 4/10

EARNINGS 📅 10 Feb 2026, 06:17 PM

Privi Speciality Chemicals Limited has released the audio recording of its analyst and investor conference call held on February 10, 2026. The call focused on the unaudited standalone and consolidated financial results for the third quarter and nine months ended December 31, 2025. The Board of Directors had approved these financial results earlier on the same day. This disclosure is a routine regulatory requirement aimed at providing transparency regarding management's discussion on company performance.

Audio recording of the Analyst/Investor Meet held on February 10, 2026, has been made available.
The call discussed financial performance for Q3 FY26 and the nine-month period ending December 31, 2025.
The investor meeting was conducted for a duration of 57 minutes between 04:00 p.m. and 04:57 p.m.
The financial results were officially approved by the Board at its meeting on February 10, 2026.

💡 Investors should listen to the recording to understand management's commentary on margin pressures and demand outlook for the speciality chemicals sector. Pay close attention to any guidance provided for the remainder of the fiscal year.

Privi Speciality Q3 FY26 PAT Surges 76% YoY to ₹78 Cr; EBITDA Margins Expand to 25.8%

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 10 Feb 2026, 03:04 PM

Privi Speciality Chemicals reported a robust Q3 FY26 with consolidated revenue growing 24% YoY to ₹611.15 crore and PAT jumping 76% to ₹77.99 crore. The company's EBITDA margin expanded by 251 bps to 25.83%, driven by operational efficiencies and a higher share of value-added products. Management reaffirmed its '5k:1k' vision, targeting ₹5,000 crore revenue and ₹1,000 crore EBITDA within 3-4 years, supported by a ₹1,200 crore CAPEX plan. Notably, the PRIGIV joint venture turned EBITDA positive during the quarter.

9M FY26 Consolidated PAT surged 94% YoY to ₹233.84 crore on revenue of ₹1,857.23 crore.
EBITDA margins improved to 25.83% in Q3 FY26, up from 23.32% in the corresponding quarter last year.
Planned CAPEX of ₹1,200 crore over 2-3 years to expand capacity and introduce new speciality molecules.
PRIGIV JV achieved positive EBITDA; Givaudan to provide ₹150 crore trade advance to reduce JV debt.
Net Debt to EBITDA ratio improved significantly to 1.63x (annualized) from 2.25x in FY25.

💡 Investors should take note of the significant margin expansion and the turnaround in the PRIGIV joint venture as key growth drivers. The clear roadmap toward doubling revenue and EBITDA over the next 3-4 years makes this a strong candidate for long-term portfolios.

Privi Speciality Q3 Net Profit Up 24.7% to ₹14.87 Cr; ₹25.5 Cr Investment in Givaudan JV

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 09 Feb 2026, 07:35 PM

Privi Speciality Chemicals reported a consolidated net profit of ₹14.87 crore for the quarter ended December 31, 2025, marking a 24.7% increase from ₹11.92 crore in the previous year. Total income for the quarter rose to ₹49,305.78 lakhs, up from ₹43,214.14 lakhs year-on-year. The board also approved a ₹50 crore equity infusion into its subsidiary, Prigiv Specialities Private Limited, with Privi contributing ₹25.5 crore to maintain its 51% stake. This investment, alongside JV partner Givaudan SA, is intended to fund growth plans and enhance future profitability.

Consolidated revenue from operations grew 14.1% YoY to ₹49,305.78 lakhs in Q3 FY26.
Net profit for the quarter increased to ₹1,486.64 lakhs compared to ₹1,192.24 lakhs in Q3 FY25.
Approved ₹25.5 crore equity investment in subsidiary Prigiv Specialities Private Limited.
JV partner Givaudan SA to contribute ₹24.5 crore (49%) to the total ₹50 crore capital infusion.
Nine-month consolidated net profit reached ₹4,491.51 lakhs, up from ₹3,548.79 lakhs in the prior year period.

💡 The company shows consistent double-digit growth in both revenue and profitability while deepening its strategic partnership with global leader Givaudan. Investors should view the continued capital commitment to its subsidiary as a positive sign for long-term capacity and revenue expansion.

Privi Speciality Q3 FY26 Revenue Up 17% to ₹507 Cr; Net Profit Declines 48% YoY

🔴 NEGATIVE ⭐ 8/10

EARNINGS 📅 09 Feb 2026, 07:30 PM

Privi Speciality Chemicals reported a 17.4% YoY growth in consolidated revenue for Q3 FY26, reaching ₹507.38 crore. However, net profit for the quarter saw a significant decline of 48.3% YoY, dropping to ₹12.07 crore from ₹23.34 crore in the previous year. The company also announced a ₹50 crore equity infusion into its subsidiary, Prigiv Specialties, in partnership with Givaudan SA to support future growth. Despite the top-line growth, profitability was impacted by higher operating expenses and finance costs.

Consolidated Revenue from operations grew 17.4% YoY to ₹507.38 crore in Q3 FY26.
Net Profit after tax fell 48.3% YoY to ₹12.07 crore compared to ₹23.34 crore in Q3 FY25.
Board approved a ₹50 crore investment in subsidiary Prigiv Specialties, with Privi contributing ₹25.5 crore (51%).
Nine-month FY26 net profit stands at ₹44.47 crore, a sharp decline from ₹90.21 crore in 9M FY25.
Finance costs for the quarter remained high at ₹21.98 crore, impacting the bottom line.

💡 Investors should exercise caution as the company is facing significant margin pressure despite healthy revenue growth. Monitor the progress of the Prigiv Specialties expansion and the company's ability to manage rising operational costs in the coming quarters.

Privi Speciality Chemicals Q3 Net Profit Surges 138% to ₹39.06 Cr; ₹50 Cr JV Investment Approved

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 09 Feb 2026, 07:16 PM

Privi Speciality Chemicals reported a robust performance for Q3 FY26, with consolidated revenue from operations growing 13.6% YoY to ₹490.87 crore. The company's net profit witnessed a massive surge of 138% YoY, reaching ₹39.06 crore compared to ₹16.38 crore in the corresponding quarter of the previous year. Additionally, the board approved a ₹50 crore equity infusion into its subsidiary, Prigiv Specialties, with Privi contributing ₹25.5 crore (51%) and JV partner Givaudan SA contributing the remainder. This strategic investment is aimed at supporting growth plans and enhancing future profitability.

Consolidated Revenue from operations increased 13.6% YoY to ₹490.87 crore in Q3 FY26.
Net Profit for the quarter surged 138% YoY to ₹39.06 crore from ₹16.38 crore in Q3 FY25.
Basic and Diluted EPS improved significantly to ₹10.00 from ₹4.19 in the year-ago period.
Approved a ₹50 crore equity investment in Prigiv Specialties Private Limited in a 51:49 ratio with Givaudan SA.
Nine-month net profit for the period ended December 31, 2025, stands at ₹120.73 crore, up from ₹86.51 crore YoY.

💡 The significant expansion in margins and strong bottom-line growth make this a positive result for shareholders. Investors should monitor the progress of the Prigiv Specialties JV investment as it is expected to drive future revenue growth.

Privi Speciality Chemicals to Hold Q3 & 9M FY26 Earnings Call on February 10, 2026

🟡 NEUTRAL ⭐ 4/10

EARNINGS 📅 02 Feb 2026, 03:30 PM

Privi Speciality Chemicals Limited has scheduled its earnings conference call for Tuesday, February 10, 2026, at 4:00 PM IST. The management will discuss the company's financial and operational performance for the third quarter and the nine-month period ending December 31, 2025. This call provides an opportunity for investors and analysts to interact with the management team regarding recent business developments and future outlook. A transcript of the call will be made available on the company's website within five working days post-conclusion.

Earnings call scheduled for February 10, 2026, at 4:00 PM IST.
Discussion will cover financial results for Q3 and 9M ended December 31, 2025.
Management team will be present to address questions from institutional investors and analysts.
Primary access numbers for the call are +91 22 6280 1309 and +91 22 7115 8210.
Transcript to be uploaded on the company website within 5 working days.

💡 Investors should attend or review the transcript of the call to understand management's commentary on margin pressures and demand recovery in the speciality chemicals segment. Key focus should be on the company's guidance for the final quarter of FY26.

Privi Speciality Chemicals Submits SEBI Compliance Certificate for Q3 FY26

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 06 Jan 2026, 05:47 PM

Privi Speciality Chemicals Limited has submitted its compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended December 31, 2025. The certificate, issued by MUFG Intime India Private Limited, confirms that securities received for dematerialization were processed within prescribed timelines. It further verifies that the security certificates were mutilated and cancelled after due verification. This is a standard procedural filing required by all listed companies in India to ensure the integrity of the dematerialization process.

Compliance certificate submitted for the third quarter ended December 31, 2025.
Issued by Registrar and Share Transfer Agent MUFG Intime India Private Limited.
Confirms dematerialization requests were processed within prescribed timelines.
Confirms physical certificates were mutilated and cancelled after verification.

💡 No action is required as this is a routine regulatory compliance filing. Investors should focus on upcoming quarterly financial results for performance assessment.

Privi Speciality Chemicals to Close Trading Window from Jan 1 for Q3 FY25 Results

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 24 Dec 2025, 11:25 AM

Privi Speciality Chemicals Limited has announced the closure of its trading window starting January 1, 2025, in compliance with SEBI Insider Trading regulations. This closure is ahead of the declaration of the un-audited financial results for the third quarter and nine months ending December 31, 2025. The restriction applies to all designated employees, directors, and key managerial personnel. The window will remain closed until 48 hours after the financial results are officially declared to the exchanges.

Trading window closure effective from January 1, 2025.
Closure pertains to the Q3 and nine-month financial results ending December 31, 2025.
Applies to all Designated Employees, Directors, and Key Managerial Personnel (KMPs).
Trading window will reopen 48 hours after the announcement of financial results.

💡 This is a routine regulatory filing with no immediate impact on stock fundamentals; investors should monitor the upcoming Q3 results for actual performance metrics.

Privi Speciality Chemicals Approves Merger of PFSPL and PBPL; Swap Ratio Set at 1:135

🟢 POSITIVE ⭐ 8/10

M&A 📅 19 Dec 2025, 07:26 PM

The Board of Privi Speciality Chemicals (PSCL) has approved the amalgamation of Privi Fine Sciences (PFSPL) and its wholly-owned subsidiary Privi Biotechnologies (PBPL) into the parent company. For the merger of PFSPL, the company will issue 1 equity share for every 135 shares held by PFSPL shareholders, while PBPL shares will be cancelled as it is a 100% subsidiary. This consolidation aims to integrate 'green science' and biotech R&D capabilities, bringing assets worth approximately ₹324 crore into the main entity. Post-merger, the promoter holding will marginally increase from 69.89% to 70.64%.

Share exchange ratio of 1 equity share of PSCL for every 135 equity shares of Privi Fine Sciences (PFSPL)
Promoter shareholding to increase from 69.89% to 70.64% post-amalgamation
Consolidation of assets totaling approximately ₹32,394.77 Lakhs from the two transferor companies
Integration of a 1,52,444.46 square meter 'green science' land parcel in Jhagadia, Gujarat
Total equity share capital to increase from 3,90,62,706 to 4,07,94,775 shares

💡 Investors should view this as a strategic consolidation that simplifies the corporate structure and integrates specialized R&D and green chemistry units. Monitor the timeline for NCLT approvals and the subsequent operational synergies in the aroma chemicals segment.

View All PRIVISCL Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Consolidated total income grew 19.3% in FY25 to INR 2,121.84 Cr. In H1 FY26, revenue grew 24% YoY to INR 1,246.08 Cr, driven by a 20% QoQ growth between Q2 and Q1 FY26 from flagship and newly introduced products.

Geographic Revenue Split

Exports account for over 65% of total revenue, reaching customers in more than 30 countries. Domestic sales contribute the remaining balance of less than 35%.

Profitability Margins

Profit After Tax (PAT) for FY25 grew 92.6% to INR 184.61 Cr from INR 95.84 Cr. H1 FY26 PAT grew 94% YoY to INR 147.76 Cr, reflecting improved management of raw material costs and higher volumes.

EBITDA Margin

EBITDA margin for FY25 was approximately 22.3%. H1 FY26 EBITDA margin improved to 25.94%, with Q2 FY26 reaching a record high of 26.83% (up 59% YoY in absolute terms to INR 182.14 Cr) due to byproduct value addition and de-bottlenecking.

Capital Expenditure

Total capital expenditure of INR 178 Cr is allocated for the PRIGIV joint venture and a greenfield facility in Mahad, Maharashtra. Phase-1 expansion was completed ahead of schedule.

Credit Rating & Borrowing

CRISIL Ratings monitors gearing with a downward sensitivity factor if it sustains above 1.15 times. Upward rating factors include strengthening the business profile and maintaining a working capital cycle below 150 days.

⚙️ Operational Drivers

Raw Materials

Specific raw materials include pinene-based, citral-based, and phenol-based chemicals, as well as various crude oil derivatives.

Import Sources

Over 55% of raw materials are imported from global markets to ensure supply continuity and cost-effectiveness.

Capacity Expansion

Current installed capacity is 48,000 MTPA. Planned expansion will increase available capacity to 54,000 MTPA by January 2026. Long-term vision targets a '5K, 1K' goal over the next 3-4 years.

Raw Material Costs

Raw material costs are stabilized through long-term contracts and strategic hedging. Management of these costs was a primary driver for the 92.6% increase in PAT during FY25.

Manufacturing Efficiency

Capacity utilization reached 92% in H1 FY26. Efficiency is driven by continuous innovation and value addition through byproducts.

📈 Strategic Growth

Expected Growth Rate

20%

Growth Strategy

Growth will be achieved through the '5K, 1K' vision (targeting INR 5,000 Cr revenue and INR 1,000 Cr EBITDA), the PRIGIV JV which will manufacture 42 exclusive products for Givaudan SA, and increasing capacity to 54,000 MTPA by Jan 2026.

Products & Services

Aroma and fragrance chemicals (over 75 specialized products) used as ingredients for manufacturing fragrances for the global FMCG and flavor industries.

Brand Portfolio

Privi, PRIGIV (Joint Venture).

New Products/Services

The PRIGIV JV is ramping up to manufacture 42 high-end products exclusively for Givaudan SA, which is expected to provide meaningful contributions in the coming years.

Market Expansion

Expansion is focused on high-end product lines for global leaders and increasing reach beyond the current 30+ countries.

Market Share & Ranking

India's leading manufacturer, supplier, and exporter of aroma and fragrance chemicals.

Strategic Alliances

Strategic partnership and 51% Joint Venture (PRIGIV) with Givaudan SA for exclusive product manufacturing.

🌍 External Factors

Industry Trends

The aroma chemicals market is shifting toward sustainable and advanced solutions. Privi is positioned in the top 5% of global manufacturers for sustainability with an EcoVadis Gold Certification.

Competitive Landscape

Key dynamics involve competing with Chinese manufacturers and global aroma chemical firms by leading with purpose and responsible growth.

Competitive Moat

Durable advantages include the strategic JV with Givaudan SA, process intensification capabilities, and a 'Gold' sustainability rating which acts as a high entry barrier for competitors.

Macro Economic Sensitivity

Highly sensitive to crude oil price volatility and USD/INR exchange rate fluctuations due to the high volume of imports (55%) and exports (65%).

Consumer Behavior

Increasing consumer and regulatory demand for sustainable and transparently sourced fragrance ingredients.

Geopolitical Risks

Competition from China is a noted threat, which the company mitigates through its sustainability differentiator and long-standing global FMCG relationships.

⚖️ Regulatory & Governance

Industry Regulations

Operations comply with Indian Accounting Standards (Ind AS) and relevant provisions of the Companies Act, 2013. Adheres to global manufacturing standards for aroma chemicals.

Environmental Compliance

Compliant with ISO 14001:2015 and ISO 45001:2018. Holds EcoVadis Gold Certification for sustainability performance.

Taxation Policy Impact

Received INR 9 Cr in state incentives during H1 FY26 from Gujarat and Maharashtra. The company is pursuing 'Ultra Mega' status to extend incentive eligibility to a 20-year period.

Legal Contingencies

Statutory auditors reported no instances of fraud by officers or employees during the year under Section 143(12) of the Act.

⚠️ Risk Analysis

Key Uncertainties

Foreign exchange rate risk (USD/INR) and raw material price volatility (crude derivatives) are the primary uncertainties impacting financial performance.